Inderal

(propranolol hydrochloride)

ApprovedSmall molecule

Propranolol is used to treat high blood pressure, heart conditions, and to reduce the physical symptoms of anxiety like trembling and rapid heartbeat. It can also be used to prevent migraines and reduce the risk of heart problems after a heart attack.[2] Inderal is currently approved and in use across 30 indications[4].[1]

Inderal is one of 693 small molecule programs targeting Double Outlet Right Ventricle. It is currently in Approved.

Indications

Total Trials

Active Trials

692

Competitors

Pipeline

Status by Indication[4][1]

Indication

Double Outlet Right VentricleActive, not recruiting

HemangiomaUnknown

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

Cardiac ArrhythmiaUnknown

Migraine DisorderUnknown

StrokeUnknown

Tetralogy of FallotActive, not recruiting

Cutaneous MelanomaActive, not recruiting

HemorrhageActive, not recruiting

Angina PectorisUnknown

Double Outlet Right VentriclePhase 1

Active, not recruiting

HemangiomaPreclinical

Unknown

Gastroesophageal Junction AdenocarcinomaPhase 2

Active, not recruiting

Cardiac ArrhythmiaPreclinical

Unknown

Migraine DisorderPreclinical

Unknown

StrokePreclinical

Unknown

Tetralogy of FallotPhase 1

Active, not recruiting

Cutaneous MelanomaPhase 2

Active, not recruiting

HemorrhagePhase 2/Phase 3

Active, not recruiting

Angina PectorisPreclinical

Unknown

Showing 10 of 30 indications

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Inderal

Mylan Pharmaceuticals Inc

Approved

1 2

Lenvima

Eisai

Preclinical

6 3

Imjudo

AstraZeneca

Preclinical

5 4

Vizimpro

Pfizer

Preclinical

4 5

Ofev

Boehringer Ingelheim

Preclinical

7 6

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 7

Remeron

OOrganon and Co

Preclinical

1 8

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 9

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 10

REGN2810

Regeneron

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Menopause

NCT06787066

Phase 2Active, not recruiting

Urothelial Carcinoma

NCT04848519

Phase 1Recruiting

Non-Small Cell Lung Cancer

NCT05979818

Q2 2027

Phase 2Recruiting

Ovarian Cancer

NCT07125391

Q4 2027

Post-ApprovalRecruiting

Sex Differences

NCT05997732

Q3 2028

Phase 2Recruiting

Kaposi Sarcoma

NCT06445166

Clinical

Trials by Indication[1]

Propranolol5 trials

Fasting Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg

Completed· Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc·Phase 1·NCT00647816·100 enrolled

Food Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg

Completed· Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc·Phase 1·NCT00647608·98 enrolled

Propranolol Treatment of Traumatic Memories (PTTM)

Unknown status·—·N/A·NCT01069159·66 enrolled

Show 2 more trials

Use of Propranolol Hydrochloride in the Treatment of Metastatic STS

Unknown status·—·Phase 2·NCT03108300·50 enrolled

Propranolol Treatment for Postoperative Chylothorax

Recruiting·JJune Wu·Phase 1/2·NCT06833320·50 enrolled

Post-Traumatic Stress Disorder2 trials

Posttraumatic Stress Disorders in Police, Correctional Service Officers, and 911 Operators

Unknown status·—·Phase 2·NCT03152175·64 enrolled

Effect of Prophylactic, Perioperative Propranolol on Peri- and Postoperative Complications in Patients With Post Traumatic Stress Disorder

Terminated·UUniversity of California, San Francisco·Approved·NCT01555554·59 enrolled

Melanoma2 trials

Efficacy of Propranolol Treatment to Prevent Melanoma Progression

Suspended·UUniversity Hospital, Geneva·Phase 2·NCT01988831·450 enrolled

Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery

Suspended·RRoswell Park Cancer Institute·Phase 1/2·NCT03384836·47 enrolled

Sex Differences2 trials

Sex Differences in Sympathetic Vascular Reactivity at High Altitude

Completed·UUniversity of Alberta·N/A·NCT05525416·17 enrolled

Sympathetic Neurovascular Transduction: Role of Adrenergic Receptors and Sex Differences

Recruiting·UUniversity of Alberta·Phase 4·NCT05997732·30 enrolled

Fasting Conditions2 trials

A Relative Bioavailability Study of Propranolol Hydrochloride 160 mg Tablets Under Fasting Conditions

Completed·AActavis Inc.·Phase 1·NCT00865215·60 enrolled

A Relative Bioavailability Study of Propranolol HCl 160 mg Tablets Under Non-fasting Conditions

Completed·AActavis Inc.·Phase 1·NCT00864747·60 enrolled

20 more indications

Gastroesophageal Junction Adenocarcinoma1 trial

Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma

Recruiting·RRoswell Park Cancer Institute·Phase 2·NCT05651594·40 enrolled

Prolonged Labor1 trial

Propranolol Rescue of Prolonged Labor

Terminated·LLisa Levine·Phase 3·NCT04299438·164 enrolled

Obesity1 trial

Sex Disparities in Hypoxic Vasodilation and Impact of Obesity

Recruiting·UUniversity of Missouri-Columbia·Phase 1·NCT05219799·72 enrolled

CAR1 trial

Beta-blocker Administration for Cardiomyocyte Division

Recruiting·WWeill Medical College of Cornell University·Phase 1·NCT04713657·40 enrolled

Non-Small Cell Lung Cancer1 trial

Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer

Recruiting·SSecond Xiangya Hospital of Central South University·Phase 1·NCT05979818·6 enrolled

Hemorrhage1 trial

PROpranolol for Cerebral Hemorrhage-ASsociated pnEumonia (PRO-CHASE)

Completed·—·Phase 2/3·NCT05419193·168 enrolled

Fallopian Tube Cancer1 trial

Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01504126·32 enrolled

Recurrent or Metastatic Solid Tumors1 trial

Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery

Completed·WWilliam Carson·Phase 1·NCT02013492·1 enrolled

Chronic pain1 trial

Reconsolidation Therapy With Propranolol as a Treatment for Chronic Pain

Completed·UUniversité de Sherbrooke·Phase 2·NCT05085782·48 enrolled

Mechanical Ventilation1 trial

Propranolol as an Anxiolytic to Reduce the Use of Sedatives From Critically-ill Adults Receiving Mechanical Ventilation

Completed·OOttawa Hospital Research Institute·Phase 3·NCT04467086·72 enrolled

Kaposi Sarcoma1 trial

Propranolol for the Treatment of Kaposi Sarcoma in Adults

Recruiting·WWashington University School of Medicine·Phase 2·NCT06445166·25 enrolled

Type 2 Diabetes1 trial

A Single-Dose Crossover Study of MK0893 in Patients With Type 2 Diabetes (0893-019 AM4)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00902161·22 enrolled

Oral1 trial

Behavioral and Pharmacological Reconsolidation Interference in Misophonia

Completed·IIcahn School of Medicine at Mount Sinai·Phase 1·NCT05928689·141 enrolled

Urothelial Carcinoma1 trial

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

Active, not recruiting·EEmory University·Phase 2·NCT04848519·6 enrolled

Prostate Cancer1 trial

Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery

Terminated·WWake Forest University Health Sciences·Phase 2·NCT03152786·46 enrolled

Menopause1 trial

Sympathetic Vascular Transduction Across the Menopause Transition: Contributing Mechanisms

Recruiting·UUniversity of Missouri-Columbia·Phase 1·NCT06787066·75 enrolled

Tardive Dyskinesia1 trial

Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia

Withdrawn·EEmory University·Phase 2/3·NCT03254186

Bladder Cancer1 trial

Propranolol Adjuvant Treatment of Bladder Cancer

Unknown status·—·Phase 2·NCT04493489·242 enrolled

Hemangioma1 trial

Efficacy Evaluation of Propranolol Treatment of Hepatic Hemangioma

Terminated·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1/2·NCT03633747·8 enrolled

Ovarian Cancer1 trial

Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer: A Prospective, Multicenter, Phase II Clinical Study

Recruiting·BBai-Rong Xia·Phase 2·NCT07125391·136 enrolled

Sources

References

[1]
ClinicalTrials.gov — 33 trial records for propranolol hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Inderal drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — propranolol hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for propranolol hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[5]
SEC EDGAR — Mylan Pharmaceuticals Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Beta-2 Adrenergic Receptor Antagonist; Beta-1 Adrenergic Receptor Antagonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Mylan Pharmaceuticals Inc

Inderal

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q4 2027

Q3 2028

Trials by Indication[1]

Propranolol5 trials

Post-Traumatic Stress Disorder2 trials

Melanoma2 trials

Sex Differences2 trials

Fasting Conditions2 trials

Gastroesophageal Junction Adenocarcinoma1 trial

Prolonged Labor1 trial

Obesity1 trial

CAR1 trial

Non-Small Cell Lung Cancer1 trial

Hemorrhage1 trial

Fallopian Tube Cancer1 trial

Recurrent or Metastatic Solid Tumors1 trial

Chronic pain1 trial

Mechanical Ventilation1 trial

Kaposi Sarcoma1 trial

Type 2 Diabetes1 trial

Oral1 trial

Urothelial Carcinoma1 trial

Prostate Cancer1 trial

Menopause1 trial

Tardive Dyskinesia1 trial

Bladder Cancer1 trial

Hemangioma1 trial

Ovarian Cancer1 trial

References

Drug Info

Quick Facts

Related News